Department of Gastroenterology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
Department of Hematology, Seoul St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Republic of Korea.
PLoS One. 2020 Sep 25;15(9):e0239740. doi: 10.1371/journal.pone.0239740. eCollection 2020.
Studies on gastrointestinal (GI) tract involvement in mantle cell lymphoma (MCL) are lacking. We investigated the clinical characteristics and prognosis of MCL with GI tract involvement.
We retrospectively analyzed 64 patients diagnosed with MCL from January 2009 to April 2017. At the time of MCL diagnosis, patients who were identified to have GI involvement by endoscopic or radiologic examination were assigned to the GI-MCL group. The other patients were assigned to the non GI-MCL group.
The GI-MCL group included 28 patients (43.8%). The most common endoscopic finding of MCL was lymphomatous polyposis (20/28, 71.4%). The GI-MCL group had higher stage and International Prognostic Index status (P = 0.012 and P = 0.003, respectively). Among the total 51 GI lesions in the GI-MCL group, 31.4% (16/51) were detected only by endoscopic examinations and were not detected on CT or PET-CT. The cumulative incidence of recurrence was higher in the GI-MCL group compared with the non GI-MCL group but the difference was not statistically significant (P = 0.082). Stage (HR 1.994, 95% CI 1.007-3.948) and auto PBSCT (HR 0.133, 95% CI 0.041-0.437) were identified as independent predictive factors for recurrence. Recurrences at GI tract were identified in 59.1% (13/22) and 11.1% (2/18) of the GI-MCL and non GI-MCL group, respectively. Among 15 GI tract recurrences, five recurrences were detected only with endoscopic examinations.
Endoscopy can reveal the GI involvement of MCL that is not visualized by radiological imaging. Endoscopic examinations are recommended during staging workup and the follow-up period of MCL patients.
关于套细胞淋巴瘤(MCL)胃肠道(GI)受累的研究较少。我们研究了伴有胃肠道受累的 MCL 的临床特征和预后。
我们回顾性分析了 2009 年 1 月至 2017 年 4 月期间诊断为 MCL 的 64 例患者。在 MCL 诊断时,通过内镜或影像学检查发现有 GI 受累的患者被分配到 GI-MCL 组。其他患者被分配到非 GI-MCL 组。
GI-MCL 组包括 28 例患者(43.8%)。MCL 最常见的内镜表现是淋巴瘤性息肉(20/28,71.4%)。GI-MCL 组的分期和国际预后指数(IPI)状态更高(P=0.012 和 P=0.003)。在 GI-MCL 组的 51 个 GI 病变中,31.4%(16/51)仅通过内镜检查发现,而 CT 或 PET-CT 未发现。GI-MCL 组的复发累积发生率高于非 GI-MCL 组,但差异无统计学意义(P=0.082)。分期(HR 1.994,95%CI 1.007-3.948)和自体 PBSCT(HR 0.133,95%CI 0.041-0.437)被确定为复发的独立预测因素。GI-MCL 组和非 GI-MCL 组分别有 59.1%(13/22)和 11.1%(2/18)的患者出现胃肠道复发。在 15 例胃肠道复发中,5 例仅通过内镜检查发现。
内镜可揭示影像学检查未发现的 MCL 胃肠道受累。建议在 MCL 患者的分期检查和随访期间进行内镜检查。